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Abstract 
Primary immune thrombocytopenia is an autoimmune disorder in which platelet 
destruction is a consequence of both B- and T-cell dysregulation. Flow cytometry 
was used to further characterize the B- and T-cell compartments in a cross-
sectional cohort of 26 immune thrombocytopenia patients including antiplatelet 
antibody positive (n=14) and negative (n=12) patients exposed to a range of 
therapies, and a cohort of matched healthy volunteers. Markers for B-cell 
activating factor and its receptors, relevant B-cell activation markers (CD95 and 
CD21) and markers for CD4+ T-cell subsets, including circulating T follicular 
helper-like cells were included. Our results indicate that an expanded population 
of CD95+ naive B-cells correlated with disease activity in immune 
thrombocytopenia patients regardless of treatment status. A population of CD21- 
naive B-cells was specifically expanded in autoantibody-positive immune 
thrombocytopenia patients. Furthermore, the B-cell maturation antigen, a 
receptor for B-cell activating factor, was consistently and strongly upregulated 
on plasmablasts from immune thrombocytopenia patients. These observations 
have parallels in other autoantibody-mediated diseases and suggest that loss of 
peripheral tolerance in naive B-cells may be an important component of immune 
thrombocytopenia pathogenesis. Moreover, the B-cell maturation antigen 
represents a potential target for plasma cell directed therapies in immune 
thrombocytopenia. 
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Introduction 
Primary immune thrombocytopenia (ITP) is a clinical diagnosis given to patients 
with an unexplained, prolonged isolated thrombocytopenia. ITP is a rare but 
chronic condition in adults and is associated with significant bleeding-related 
morbidity and mortality.
1
 The condition is characterized by both platelet 
destruction and impaired platelet production. A role for platelet-directed 
antibodies was established in the 1960s with transfer experiments showing that 
thrombocytopenia could be induced by transfer of the gamma-globulin fraction 
of ITP patient serum.
2
 Using the most sensitive assays, antibodies binding 
platelet membrane glycoproteins are present in approximately 50% of patients.
3
 
The mechanism by which B-cell tolerance is lost is debated, but an elevated 
serum level of B-cell Activating Factor (BAFF) is likely to be an important 
contributing factor.
4
 BAFF drives B-cell maturation, promotes B-cell survival and 
augments immunoglobulin production by binding three surface B-cell receptors: 
BAFF receptor (BAFF-R), transmembrane activator and calcium modulator and 
cyclophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA).
5
 An 
expanded CD95 (Fas receptor) positive population of B-cells has also been 
described in ITP and there are reports of fewer regulatory B-cells, defined both 
as CD24
hi
CD38
hi
 B-cells and by IL-10 production.
6,7
 
 
A modern view of ITP pathogenesis places these B-cell abnormalities within a 
complex network of abnormalities affecting multiple immune cell lineages. T-
cells, in particular, contribute to platelet destruction both by facilitating the 
production of class-switched, high affinity autoantibody and through B-cell 
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independent mechanisms such as cell-mediated cytotoxicity directed against 
platelets.
8
 The latter may be the primary mechanism of disease in a subset of 
patients with no detectable anti-platelet antibodies.
9
 High-affinity autoantibody 
production is facilitated by T follicular helper cells (TFH), a subset recently 
reported to be expanded proportional to germinal centre and plasma cell 
numbers within the spleens of ITP patients.
10
 
 
This study sought to extend existing knowledge of immune dysregulation in ITP 
by performing detailed flow cytometry-based immunophenotyping of the B- and 
T-cell compartments. An interest in the therapeutic potential of belimumab, an 
anti-BAFF humanized monoclonal antibody, led us to focus on BAFF and its 
receptors in B-cells. While recent studies of immune populations in splenectomy 
specimens from patients with ITP have by their nature enrolled patients with 
refractory disease receiving significant immunodulatory therapy, we chose to 
enroll a cross-section of ITP patients in order to ensure the broadest possible 
applicability of our findings. Therefore autoantibody positive and negative ITP 
patients were recruited across a range of platelet counts and prior treatments 
including rituximab and splenectomy despite the known effects of these 
therapies on B-cells with the intention of identifying candidate biomarkers of 
relevance to future clinical trials. An initial analysis was performed comparing 
splenectomy- and rituximab-naive ITP patients with healthy volunteers, and 
significant results were evaluated in the larger cohort.  
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Methods 
Patients and healthy volunteers 
A cross-sectional cohort of adult patients with a clinical diagnosis of chronic ITP 
was recruited from patients in the UK ITP registry visiting the outpatient clinic of 
the Royal London Hospital Department of Haematology (Table 1 and Table S2). 
All patients able to give informed consent were considered for inclusion; the only 
exclusion criterion was ongoing immunosuppressive or cytotoxic therapy for a 
non-ITP diagnosis (one renal transplant recipient). Recruitment was stratified to 
give approximately equal numbers of patients by anti-platelet antibody status. 
All participants provided one venous blood sample; a subset of patients provided 
a second sample at a later time-point. None of the patients had received a 
platelet transfusion in the 10 days prior to or intravenous immunoglobulin in the 
21 days prior to venesection. 
 
Age- (within 10 years) and sex-matched healthy volunteers (HV) were recruited 
locally from within the GSK donor pool in parallel with the ITP patients. Ethical 
approval was obtained from the National Research Ethics Service, London REC, 
Ref. 07/H0718/57 (ITP patients) and National Research Ethics Service, 
Hertfordshire REC, Ref. 07/H0311/103 (GSK donor pool). The human biological 
samples were sourced ethically and their research use was in accord with the 
terms of the informed consents. 
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Anti-platelet autoantibodies. 
EDTA-anticoagulated venous blood was tested within three days of venesection. 
Direct tests (for platelet bound IgG and IgM) were determined using the platelet 
immunofluorescence test (PIFT)
11
 and by the monoclonal antibody-specific 
immobilization of platelet antigens (MAIPA) assay
12
 to determine whether there 
was platelet bound IgG localised to platelet glycoproteins (GP)IIb/IIIa, GPIa/IIa 
or GPIb/IX. A patient was considered to have platelet autoantibodies if the 
results of the direct PIFT or the direct MAIPA assay were greater than the mean 
+3 standard deviations of the values obtained for platelets obtained from at least 
three normal blood donors on the same day. These investigations were 
performed at the Histocompatibility and Immunogenetics Laboratory, NHS 
Blood & Transplant – Filton. 
Flow cytometry 
Venous blood was collected into lithium heparin tubes (Fisher Scientific) and 
arrived at the laboratory within 3 hours. Peripheral blood mononuclear cells 
(PBMC) were prepared by density gradient centrifugation using Ficoll-Paque 
Plus (GE Healthcare).  For transitional B-cells, PBMC were pre-incubated with 
MitoTracker green (Invitrogen) at 10nM concentration for 20 minutes at 37°C, 
then washed before adding antibodies.
13
 For B-cell immunophenotyping, a 
common antibody panel consisting of anti-CD38 (PE-Cy7, eBioscience 25-0389), 
anti-CD27 (APC, eBioscience 17-0279), anti-CD19 (APC-Cy7, BD Biosciences 
557791), anti-IgD (biotin, BD Biosciences cat 555777) and anti-CD3 (Pac Orange, 
Invitrogen CD0330) was used, with the following antibodies added to individual 
tubes as required: anti-CD10 (PE, BD Bioscience 555375), anti-IgG (FITC, BD 
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Biosciences 555786), anti-IgM (PerCP Cy5.5, BioLegend 314512), anti-CD95 (PE, 
BioLegend 305608), anti-CD21 (PE, BD Biosciences 555422), anti-CD24 (PerCP 
eFluor710, eBioscience 46-0247), anti-BCMA (PerCP eFluor710, custom GSK 
conjugate), anti-BAFFR (FITC, BioLegend 316904), and anti-TACI (PE, BioLegend 
311906).  
 
For T-cell immunophenotyping, a common skeleton consisting of anti-CD3 (APC-
Cy7, BioLegend 300318), anti-CD4 (Pacific Blue, BioLegend 317429), anti-
CD45RA (PerCP Cy5.5, eBioscience 45-0458), and anti-CXCR5 (PE, R&D Systems 
FAB190P) was supplemented with anti-CCR6 (PE-Cy7, BioLegend 353418), anti-
PD1 (APC, BD Biosciences 558694) and anti-CXCR3 (FITC, R&D Systems 
FAB160F) for general T-cell subsets/T-follicular helper cells and with anti-CD25 
(PE-Cy7, BD Biosciences 557741) and anti-CD127 (AF647, BD Biosciences 
558598) for regulatory T-cells. Normal rat serum and normal mouse serum was 
added to all tubes to minimize non-specific binding (Table S1). 
 
In each case 1x10
6
 cells were stained in 100uL at room temperature in the dark 
for 20 minutes. Tubes containing anti-IgD were then stained with streptavidin 
eFluor 450 (eBiosciences 48-4317) for a further 20 minutes. 
 
Cells were resuspended in 200uL FACS buffer and acquired immediately on a BD 
Canto II (BD Biosciences). A compensation matrix was calculated using BD 
CompBeads for all stains except Mitotracker, where positive and negative live 
cells were used. Gating was performed in FlowJo vX (Miltenyi). B-cell gating is 
shown (Figure 1A). CD4+ T-cells are gated as CD4+CD3+ cells in the lymphocyte 
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gate. Memory CD4+ T-cells are gated as CD45RA-. Tregs are gated as a discrete 
CD25 high, CD127 low population. For quality assurance, each ITP sample was 
run in parallel with a HV sample using the same antibody mixes; only technically 
adequate samples were included in the analysis. 
 
BAFF Enzyme Linked Immunosorbent Assay (ELISA) 
Serum was extracted from venous blood collected into serum tubes and 
centrifuged at 2000rpm for 15 minutes. This was stored at -80°C until the ELISA 
could be performed, in three overlapping batches. The Quantikine Human 
BAFF/BLyS/TNFSF13B Immunoassay (R&D Systems, cat # DBLYS0) was used 
according to the manufacturer’s instructions. 
 
Data analysis and statistical methods. 
The main analysis was performed using a 'patient-level' cohort, comprising one 
sample per ITP patient and a matched HV sample, stratified by prior 
splenectomy or rituximab use. Where patients provided multiple samples, the 
time-point with the lowest platelet count was chosen. Twenty-six ITP patients 
fulfilled these criteria for the B-cell analysis and 18 patients for the T-cell 
analysis with healthy volunteers matched to each analysis. Two patients had 
FACS data without a platelet count; these were only excluded from analyses 
requiring a platelet count. Four patients in the ITP cohort had platelet count and 
FACS data from multiple time-points, allowing a repeated measures analysis. 
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All data analysis was performed using R (www.r-project.org). Between group 
comparisons were performed using pairwise Wilcoxon signed-rank tests, except 
for a repeated measures analysis of the association between platelet count and 
CD95+ naive B-cells where a linear mixed effects model was implemented using 
the nlme package in R. An alpha level of 0.05 was considered significant. 
 
Results 
Major B-cell populations. 
A cross-sectional cohort of 26 ITP patients, 12 of whom had active disease (i.e. 
platelet count < 50×10
9
/L) was matched to 26 HV (Table 1). Nine ITP patients 
were on no current treatment and had not received prior B-cell modulating 
therapies; 12 patients had previously received rituximab or a splenectomy and a 
number were also receiving other agents including mycophenolate, azathioprine 
and romiplostim (Table S2). Fourteen ITP patients had detectable platelet-bound 
IgG or IgM antibodies, and seven of these had antibodies with the following 
specificities: GPIIb/IIIa (4), GPIb/IX (1) or both GPIIb/IIIa and GPIb/IX (2). 
 
The major B-cell subsets (i.e. B-cells overall, naive (CD27–IgD+) B-cells, 
CD27+IgD+ memory B-cells, CD27+IgD– memory B-cells, ‘double-negative’ 
(CD27–IgD– ) B-cells and circulating plasmablasts gated as shown in Figure 1A) 
were compared between splenectomy- and rituximab-naive (‘untreated’) ITP 
patients (n=14) and HV. No differences were observed in these headline 
populations between ITP patients and HV (Figure 1B). There were also no 
differences between untreated ITP patients and HV in the most immature 
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population of peripheral blood B-cells, transitional B-cells, despite phenotyping 
these in detail (Figures 1C-D). 
 
B-cell expression of CD95 (Fas receptor) and CD21 (Complement receptor 2). 
There were, however, differences in the B-cell surface expression of CD95 and 
CD21, both linked previously to autoimmune disease.
14,15
 Overall, CD95 was 
expressed in a bimodal fashion on the B-cell surface (Figure 2A) with the 
proportion of CD95+ cells increasing stepwise along the B-cell differentiation 
pathway (i.e. median proportion in HV of CD95+ naive B-cells = 1%, IgD+CD27+ 
memory B-cells = 16%, IgG+IgD-CD27+ memory B-cells = 43% and circulating 
plasmablasts = 98%, Figure 2B). In naive and IgD+CD27+ memory B-cells, there 
was a small but highly statistically significant expansion of the CD95+ population 
in untreated ITP patients compared to HV (Figure 2B). ITP patients with prior 
splenectomy or rituximab also had a higher median proportion of CD95+ 
IgD+CD27+ memory B-cells than their untreated counterparts and a positive 
association was observed with time since rituximab therapy (Figure 2C-D), 
suggesting an additional effect of B-cell depletion. This is in contrast to the 
proportion of CD95+ naive B-cells, which was increased similarly in all ITP 
patients regardless of prior rituximab and splenectomy exposure and which was 
not associated with time post-rituximab. 
 
The size of the CD95+ naive population was correlated with disease activity, with 
the largest expansion observed in those patients with platelet counts < 50x10
9
/L 
(Figure 2E). Using the four ITP patients who had been bled at a second time-
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point (ranging from 56 to 455 days between samples), including one who had 
previously had a splenectomy and one who had received rituximab 2.6 years 
prior to the first blood draw, we found that that within individual patients, an 
improving platelet count was associated with a reduction in the proportion of 
CD95+ naive B-cells (p=0.05, repeated measures using a linear mixed effects 
model, Figure 2F). Prior rituximab or splenectomy was also associated with an 
expansion of the proportion of CD95+ cells compared to HV in IgD-CD27+ 
memory B-cells (data not shown). 
 
CD21, on the other hand, was present in HV on a median 98% of naive B-cells, 
87% of IgG+IgD-CD27+ memory B-cells and 36% of plasmablasts, confirming 
other reports that this marker is lost stepwise during B-cell terminal 
differentiation (Figures 3A-B). There was a significant reduction in the 
proportion of naive B-cells expressing CD21 in untreated ITP patients compared 
with matched HV (Figure 3B). This was unrelated to disease activity (platelets < 
50x10
9
/L versus platelets ≥ 50x10
9
/L, p=0.79). Instead, this loss of CD21 on 
naive B-cells was restricted to patients with detectable platelet autoantibodies 
and appeared to be ameliorated by treatment with rituximab or splenectomy 
(Figure 3C). Median platelet counts were similar between antibody positive and 
negative patients (51.5x10
9
/L versus 56.5x10
9
/L, p=0.93). 
 
BAFF and its receptors. 
Serum BAFF levels were increased in our cohort of ITP patients overall, 
consistent with other studies. Moreover, in untreated patients there was a trend 
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toward higher serum BAFF levels in active disease (i.e. platelet count < 
50x10
9
/L) compared with patients in remission (Figure 4A). This trend was not 
seen in the treated group, most likely due to increases in serum BAFF in the 
setting of rituximab and splenectomy. This is well-described and a consequence 
of the effect of B-cell depletion on BAFF release and synthesis.
16
 There were no 
differences in serum BAFF levels by autoantibody status (data not shown). 
 
In the absence of published data on the expression of BAFF receptors following 
rituximab, we analysed both treated and untreated ITP patients. BAFFR was 
detectable on all populations of B-cells except for plasmablasts (Figure 4B). TACI 
was broadly expressed on memory B-cells and plasmablasts but present on only 
a very small population of naive B-cells (Figure 4C). There were no significant 
differences in the B-cell expression of either of these markers between HV and 
untreated ITP patients, but we observed a significant decrease in BAFF receptor 
expression on a number of B-cell populations and increase in TACI expression on 
naive B-cells in samples from ITP patients after rituximab or splenectomy 
(Figure 4C). Neither of these showed a correlation with time since last rituximab 
dose (data not shown). 
 
BCMA was primarily present on plasmablasts, but was also detected on a small 
number of double-negative (CD27-IgD-) B-cells. BCMA was markedly and 
consistently upregulated on plasmablasts in ITP (Figure 4D), irrespective of 
platelet count, prior treatment or autoantibody status (Figures 4D-F). 
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T-cell phenotype. 
Data on T-cell populations were also available for 18 ITP patients. We found a 
trend to proportionally fewer CD4+ T-cells in splenectomy- and rituximab-naive 
ITP patients compared to HV, consistent with previous reports of a reduced 
CD4:CD8 ratio in ITP (Wilcoxon p-value = 0.053, Figure 5A).
17
 We found few 
other differences within the memory T-cell, CXCR5+ memory T-cell and Treg 
populations when these were analysed as a proportion of their parent 
populations. Reduced numbers of CD4+ T-cells and memory CD4+ T-cells overall 
in our cohort of splenectomy- and rituximab-naive ITP patients resulted in a 
number of differences in subpopulations in absolute terms (Figure 5B). 
 
Discussion 
Reduced CD21 and increased CD95 expression on naive B-cells and marked 
BCMA upregulation on plasmablasts are identified as important components of 
the immune phenotype of ITP. CD95 is upregulated rapidly upon B-cell 
activation,
18
 and the ITP-specific expansion of CD95+ and of CD21– naive B-cells 
observed in this study may represent a population of autoreactive B-cells 
activated in the presence of circulating platelet autoantigens. It is known that 
self-reactive B-cells emerge from the bone marrow in reasonable quantities,
19
 
and that peripheral mechanisms of tolerance can be overcome in the presence of 
high BAFF levels.
20
 
 
Mechanistic data in support of this hypothesis comes from a recent study of B-
cells from patients with flaring SLE.
21
 Using B-cell receptor repertoire analysis by 
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next-generation sequencing, the authors demonstrated that a distinct subset of 
naive B-cells constituted an important source of autoreactive antibody secreting 
cells. This activated subset was characterized by increased CD95 expression and 
reduced expression of CD21. Although our flow panels were not designed to 
study the coexpression of these markers, these findings mirror the expanded 
CD95+ and CD21- naive B-cell populations we describe here. In SLE, this subset 
was expanded further during flaring disease, consistent with our observation 
that expansion of CD95+ naive B-cells in ITP correlated with disease activity. 
 
The loss of CD21, a receptor for C3d that interacts with CD19 to lower the 
threshold for signaling through the B-cell receptor,
22
 has been linked to a subset 
of naive B-cells in which autoreactive cells are overrepresented. Expansion of 
this CD21- naive B-cell population has been described in other immune-
mediated conditions as well as ITP and SLE including Sjogren’s syndrome, 
common variable immunodeficiency and rheumatoid arthritis.
23–25
 It is of 
interest that in our study CD21– naive B-cells were found predominantly in 
antiplatelet antibody positive patients, regardless of platelet count. This would 
be consistent with the hypothesis that even though the size of the CD95+ CD21- 
naive B-cell population was small, it plays an important role in the generation of 
autoantibody. 
 
Given this hypothesis, it would have been informative to study the expression of 
CD95 and CD21 in a cohort with non-immune thrombocytopenia. This 
population was not available to this study, but is a potential avenue of future 
research. The lack of differences in the transitional B-cell compartment is in 
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apparent contradiction to an earlier report of fewer CD24
hi
CD38
hi
 B-cells in non-
splenectomized patients with active ITP.
6
 However, the changes reported were 
subtle and only found in patients with a platelet count < 50x10
9
/L.  
Comparatively small numbers restricted our ability to perform detailed sub-
analyses and as such, it is possible that our cross-sectional cohort was not 
powered to replicate this observation. Alternatively, this may be because we 
used the gating strategy of Palanichamy et al,
13
 to distinguish three populations 
of transitional B-cells. The CD24
hi
CD38
hi
 population of the earlier report would 
represent the more immature T1-2 populations in our study. However, we were 
able to demonstrate a trend toward expansion of these early B-cell populations 
in patients post-rituximab, consistent with a previous report.
26
 
 
The dominant finding of our T-cell analysis was a CD4+ T-cell lymphopenia, most 
prominent in the memory compartment. Such a lymphopenia has not been 
described previously in ITP and should be interpreted with caution. 
Lymphopenia is a recognized consequence of therapy and four of the 16 ITP 
patients analyzed were receiving antiproliferative agents (i.e. azathioprine, 
mycophenolate).
27
 The lack of observed differences in other subsets, especially 
Tregs, may reflect the cross-sectional nature of the patient cohort, which was 
recruited across a range of disease activity. 
 
Finally, there was a strong upregulation of BCMA on plasmablasts in ITP. The 
role of BCMA in the pathogenesis of autoimmune disease is complex and 
incompletely understood. While the sole B-cell phenotype of BCMA
-/-
 mice 
appears to be impaired survival of long-lasting plasma cells,
28
 when crossed onto 
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a lupus prone background BCMA
-/-
 mice exhibited a range of pathologies 
including increased plasma cell number, elevated systemic BAFF and an 
increased titre of anti-nuclear antibody than their BCMA sufficient 
counterparts.
29
 Similarly, little is known about the regulation of BCMA 
transcription and membrane expression. Certainly Blimp-1 and IRF4 are 
important positive regulators,
30
 consistent with BCMAs predominant expression 
on plasma cells and plasmablasts, however whether BCMA regulates, or is 
regulated by, its ligands BAFF and APRIL is unknown. Additional weight for a 
role for BCMA in autoimmune disease comes from studies in SLE, where B-cell 
expression of BCMA has been shown to be elevated.
31
 Current therapies, 
including rituximab, do not target plasma cells well. The restricted tissue 
expression pattern of BCMA, its important role in plasma cell survival and its 
increased expression in ITP and other autoimmune disease together make it an 
attractive target for novel plasma cell directed therapies. 
 
Our study adds significant detail to an emerging B-cell phenotype that is shared 
between a number of antibody-mediated autoimmune diseases. This phenotype 
is characterized by expanded populations of CD95+ and CD21– naive B-cells, 
elevated levels of serum BAFF and elevated BCMA expression on plasmablasts. 
As well as ITP, aspects of this phenotype have also been observed in SLE, 
common variable immunodeficiency and rheumatoid arthritis.
23,32
 Individually, 
these autoimmune diseases are rare, but a common immune phenotype may 
streamline the development of effective therapies targeting multiple diseases. 
The CD95+ population of naive B-cells in particular is identified as warranting 
further study as a potential biomarker for this phenotype, being both correlated 
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with disease activity within and between individuals, and robust to commonly 
used B-cell modulating therapies. 
 
References 
1.  Nørgaard M, Jensen A, Engebjerg MC, et al. Long-term clinical outcomes of 
patients with primary chronic immune thrombocytopenia: A Danish 
population-based cohort study. Blood. 2011;117(13):3514-3520. 
2.  Shulman NR, Marder VJ, Weinrach RS. Similarities between known 
antiplatelet antibodies and the factor responsible for thrombocytopenia in 
idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y 
Acad Sci. 1965;124(2):499-542.  
3.  McMillan R. Antiplatelet Antibodies in Chronic Immune Thrombocytopenia 
and Their Role in Platelet Destruction and Defective Platelet Production. 
Hematol Oncol Clin North Am. 2009;23(6):1163-1175. 
4.  Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion 
protein in immune thrombocytopenia. Blood. 2009;114(26):5362-5367. 
5.  Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating 
factor and promoter polymorphisms in patients with idiopathic 
thrombocytopenic purpura. Br J Haematol. 2007;136(2):309-314. 
6.  Li X, Zhong H, Bao W, et al. Defective regulatory B-cell compartment in 
patients with immune thrombocytopenia. Blood. 2012;120(16):3318-
3325. 
7.  Martinez-Gamboa L, Mei H, Loddenkemper C, et al. Role of the spleen in 
peripheral memory B-cell homeostasis in patients with autoimmune 
thrombocytopenia purpura. Clin Immunol. 2009;130(2):199–212. 
8.  Olsson B, Andersson P-O, Jernås M, et al. T-cell-mediated cytotoxicity 
toward platelets in chronic idiopathic thrombocytopenic purpura. Nat 
Med. 2003;9(9):1123-1124. 
9.  Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated complement 
activation on platelets is a common finding in patients with immune 
thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88(2):167-174. 
10.  Audia S, Rossato M, Santegoets K, et al. Splenic TFH expansion participates 
in B-cell differentiation and antiplatelet-antibody production during 
immune thrombocytopenia. Blood. 2014;124(18):2858-2866. 
11.  Von Dem Borne  AE, Verheugt FW, Oosterhof F, Von Riesz E, De La Rivière  
AB, Engelfriet CP. A simple immunofluorescence test for the detection of 
platelet antibodies. Br J Haematol. 1978;39:195-207.  
12.  Campbell K, Rishi K, Howkins G, et al. A modified rapid monoclonal 
antibody-specific immobilization of platelet antigen assay for the detection 
   
  19
of human platelet antigen (HPA) antibodies: A multicentre evaluation. Vox 
Sang. 2007;93:289-297.  
13.  Palanichamy A, Barnard J, Zheng B, et al. Novel human transitional B cell 
populations revealed by B cell depletion therapy. J Immunol. 
2009;182(10):5982–5993. 
14.  Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas 
signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 
2000;1(6):469–474.  
15.  Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in 
innate immunity, host defense and autoimmunity. Adv Exp Med Biol. 
2005;560:125–139. 
16.  Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg J-E, Mariette X. 
Increase of B cell-activating factor of the TNF family (BAFF) after 
rituximab treatment: insights into a new regulating system of BAFF 
production. Ann Rheum Dis. 2007;66(5):700-703. 
17.  Hu Y, Ma DX, Shan NN, et al. Increased number of Tc17 and correlation 
with Th17 cells in patients with immune thrombocytopenia. PLoS One. 
2011;6(10):e26522. 
18.  Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 
(CD95)-mediated apoptosis in human B cells. J Immunol. 
1994;152(12):5624-5632. 
19.  Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig 
MC. Predominant autoantibody production by early human B cell 
precursors. Science. 2003;301(5638):1374–1377. 
20.  Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B 
cells from peripheral deletion and allows them to enter forbidden 
follicular and marginal zone niches. Immunity. 2004;20(6):785–798. 
21.  Tipton CM, Fucile CF, Darce J, et al. Diversity, cellular origin and 
autoreactivity of antibody-secreting cell population expansions in acute 
systemic lupus erythematosus. Nat Immunol. 2015;16(7):755–765. 
22.  Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign 
and self-antigens by the CD19/CD21 complex. Annu Rev Immunol. 
2000;18:393-422. 
23.  Quách TD, Manjarrez-Orduño N, Adlowitz DG, et al. Anergic responses 
characterize a large fraction of human autoreactive naive B cells 
expressing low levels of surface IgM. J Immunol. 2011;186(8):4640-4648. 
24.  Isnardi I, Ng YS, Menard L, et al. Complement receptor 2/CD21- human 
naive B cells contain mostly autoreactive unresponsive clones. Blood. 
2010;115(24):5026–5036. 
25.  Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive 
unresponsive CD21-/low B cells in sjogren’s syndrome-associated 
lymphoproliferation. Arthritis Rheum. 2013;65(4):1085-1096.  
26.  Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab 
treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 
   
  20
2007;122(2):139-145. 
27.  Ritter ML, Pirofski L. Mycophenolate mofetil: Effects on cellular immune 
subsets, infectious complications, and antimicrobial activity: Review 
article. Transpl Infect Dis. 2009;11(4):290-297. 
28.  O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the 
survival of long-lived bone marrow plasma cells. J Exp Med. 
2004;199(1):91-98. 
29.  Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD. B cell maturation 
antigen deficiency exacerbates lymphoproliferation and autoimmunity in 
murine lupus. J Immunol. 2011;186(11):6136-6147. 
30.  Deng S, Yuan T, Cheng X, Jian R, Jiang J. B-lymphocyte-induced maturation 
protein1 up-regulates the expression of B-cell maturation antigen in 
mouse plasma cells. Mol Biol Rep. 2010;37(8):3747-3755. 
31.  Zhao LD, Li Y, Smith MF, et al. Expressions of BAFF/BAFF receptors and 
their correlation with disease activity in Chinese SLE patients. Lupus. 
2010;19(13):1534-1549. 
32.  Rakhmanov M, Keller B, Gutenberger S, et al. Circulating CD21low B cells 
in common variable immunodeficiency resemble tissue homing, innate-
like B cells. Proc Natl Acad Sci U S A. 2009;106(32):13451-13456. 
   
  21
 
Tables 
Table 1. Baseline demographics, treatment received and autoantibody 
status for ITP patients and HV used in the B-cell analysis. 
 ITP HV 
Demographics   
Patients in cohort, number 26 26 
Median age, years (range) 36 (22-63) 37 (19-62) 
Gender, number (%) 
Female 
Male 
 
16 (62%) 
10 (38%) 
 
16 (62%) 
10 (38%) 
ITP duration, years (range) 7.3 (1.1-37.4)  
Prior rituximab or splenectomy 
Rituximab alone, number (%) 
Splenectomy alone, number (%) 
Both, number (%) 
 
7 (27%) 
1 (3.8%) 
4 (15%) 
 
Current thrombopoetin receptor agonist, 
number (%) 
6 (24%)  
Anti-platelet antibodies, number (%) 
Positive by direct MAIPA (IgG) 
Positive by direct PIFT  (IgG & IgM) 
Positive by direct PIFT & direct MAIPA 
 
7 (28%) 
13 (50%) 
14 (54%) 
 
   
  22
Median platelet count, ×10
9
/L (IQR)* 
52 (36-119)  
*missing=2. MAIPA (monoclonal antibody immobilization of platelet antigens); 
PIFT (platelet immunofluorescence test); IQR (interquartile range); HV (healthy 
volunteer); ITP (immune thrombocytopenia). 
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Figure Legends 
 
Figure 1. Analysis of major B-cell subsets: differences by diagnosis. (A) 
Gating strategy for B-cell subsets. (B) Major B-cell subsets expressed as a 
percentage of CD19+ cells and stratified by diagnosis (i.e. healthy volunteers or 
splenectomy- and rituximab- naive ITP patients). (C) Gating strategy for 
transitional B-cells. Mitotracker positive gate defined using expression on 
switched memory B-cells. Transitional B-cells are Mitotracker+ IgD+CD27– . T1 
transitional population is CD10+; T2 & 3 populations are distinguished by CD38 
expression.  (D) Transitional B-cell populations, expressed as a percentage of B-
cells and stratified by diagnosis as in B. Significant pairwise p-values (Wilcoxon 
signed-rank test) are shown. ritux/splen (rituximab or splenectomy); mem 
(memory). Plasmablasts are gated out of other B-cell subsets. 
 
Figure 2. CD95+ (Fas receptor+) naive B-cells are more frequent in ITP 
patients. (A) Representative gating, showing distribution of CD95+ cells across 
the major B-cell subsets. (B) Proportions of CD95+ cells across B-cell subsets, 
stratified by diagnosis (i.e. healthy volunteers or splenectomy- and rituximab- 
naive ITP patients). (C) Proportions of CD95+ naive and IgD+CD27+ B-cells 
stratified by diagnosis and prior rituximab or splenectomy. (D) Proportions of 
CD95+ naive and IgD+CD27+ B-cells by timing of rituximab, for those ITP 
patients who had received prior rituximab. (E) CD95+ cells as a proportion of 
naive B-cells, stratified by platelet count. (F) CD95+ naive B-cells by platelet 
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count for ITP patients where a second time-point is available (Δ Splenectomy; 
 ;Rituximab; o Neither). Significant pairwise p-values (Wilcoxon signed-rank 
test) are shown in B-C & E. P-value in F is generated using a repeated measures 
linear mixed effects model. PB (plasmablast); DN (IgD-CD27- B-cells); plt = 
platelet count; ritux/splen (rituximab or splenectomy). Plasmablasts are gated 
out of other B-cell subsets. 
 
Figure 3. CD21– (complement receptor 2–) naive B-cells are more frequent 
in ITP patients. (A) Representative gating, showing distribution of CD21– cells 
across the major B-cell subsets. (B) Proportions of CD21– cells across B-cell 
subsets, stratified by diagnosis (i.e. healthy volunteers or splenectomy- and 
rituximab- naive ITP patients). (C) CD21– cells as a proportion of naive B-cells, 
stratified by anti-platelet antibody status. Significant pairwise p-values 
(Wilcoxon signed-rank test) are shown. sw mem + PB (switched memory B-cells 
and plasmablasts i.e. CD27+IgD– B-cells); DN (double-negative B-cells i.e. CD27–
IgD– B-cells); nonsw memory (non-switched memory i.e. CD27+IgD+ B-cells); Ab 
(antiplatelet antibody); ritux/splen (rituximab or splenectomy). 
 
Figure 4. Analysis of serum BAFF and its receptors: BCMA is markedly 
upregulated on the surface of plasmablasts in ITP, regardless of activity or 
autoantibody status. (A) Serum BAFF, stratified by past treatment and 
diagnosis. BAFFR (B) and TACI (C) median fluorescence intensity (MFI) across 
the major B-cell subpopulations, stratified by diagnosis and prior treatment. (D) 
Plasmablast BCMA MFI, stratified by diagnosis and prior treatment. (E-F) 
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Plasmablast BCMA MFI, stratified by platelet count and autoantibody status. 
Significant pairwise p-values (Wilcoxon signed-rank test) are shown. Plt (platelet 
count); ritux/splen (rituximab or splenectomy). 
 
Figure 5. CD4+ T-cells in ITP and healthy volunteer samples by diagnosis. 
(A) T-cell populations expressed as a proportion of their parent population, 
stratified by diagnosis (i.e. healthy volunteers (white, n=18) or splenectomy- and 
rituximab- naive ITP patients (dark grey, n=9)). (B) The same T-cell populations, 
expressed in absolute numbers (healthy volunteers (white, n=9); splenectomy- 
and rituximab- naive ITP patients (dark grey, n=8)). Significant pairwise p-values 
(Wilcoxon signed-rank test) are shown. ritux/splen (rituximab or splenectomy); 
mem (memory i.e. CD45RA–). 
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Supplementary	Information	
	
Supplementary	Table	1.	Flow	cytometry	staining	panels.		
Channel	 FITC	 PE	 PerCP	Cy5.5	
PerCP-eF710	
PE-Cy7	 APC	
AF647	
APC-
Cy7	
Pac	Blue	
V450	
Am	Cyan	
Pac	Oran	
Transit	1	 Mito	
tracker	
CD10	 CD24	 CD38	 CD27	 CD19	 IgD	 CD3	
Transit	2	 Mito	
tracker	
Iso	type	 CD24	 CD38	 CD27	 CD19	 IgD	 CD3	
Activated	1	 IgG	 CD95	 IgM	 CD38	 CD27	 CD19	 IgD	 CD3	
Activated	2	 IgG	 CD21	 IgM	 CD38	 CD27	 CD19	 IgD	 CD3	
BAFFR/TACI	 BAFF	R	 TACI	 BCMA	 CD38	 CD27	 CD19	 IgD	 CD3	
BAFFR/TACI	
Iso	
BAFF	R	 (FMO)	 BCMA	 CD38	 CD27	 CD19	 IgD	 CD3	
BAFF	R	
Iso/TACI	
(FMO)	 TACI	 BCMA	 CD38	 CD27	 CD19	 IgD	 CD3	
T	reg	 CXCR3	 CXCR5	 CD45RA	 CD25	 CD127	 CD3	 CD4	 	
TFH	1	 CXCR3	 CXCR5	 CD45RA	 CCR6	 PD-1	 CD3	 CD4	 	
TFH	2	 CXCR3	 CXCR5	 CD45RA	 (FMO)	 PD-1	 CD3	 CD4	 	FMO	(‘fluorescence	minus	one’	control)	
	
	
	 	
	 2	
Supplementary	Table	2.	Immunosuppression	received	by	patients	at	time	of	first	bleed.		
	 Prior	
rituximab	
Time	since	last	
Rituximab	(years)	
Splenectomy	 Romiplostim	
at	bleed	
Other	
immunosuppression	
1	 Yes	 7.88	 No	 Yes	 No	
2	 Yes	 7.33	 No	 No	 MMF	500mg	bd	
3	 Yes	 2.61	 No	 No	 No	
4	 Yes	 2.18	 No	 Yes	 No	
5	 Yes	 1.76	 No	 Yes	 No	
6	 Yes	 1.40	 No	 No	 No	
7	 Yes	 1.28	 No	 No	 No	
8	 Yes	 4.96	 Yes	 Yes	 No	
9	 Yes	 3.26	 Yes	 No	 Aza	100mg	d	
10	 Yes	 2.00	 Yes	 Yes	 No	
11	 Yes	 1.36	 Yes	 Yes	 No	
12	 No	 	 No	 No	 No	
13	 No	 	 No	 No	 MMF	1g	bd	
14	 No	 	 No	 No	 No	
15	 No	 	 No	 No	 MMF	1g	bd	
16	 No	 	 No	 No	 MMF	250mg	bd	
17	 No	 	 No	 No	 No	
18	 No	 	 No	 No	 No	
19	 No	 	 No	 No	 MMF	250mg	d	
20	 No	 	 No	 NA	 No	
21	 No	 	 No	 No	 No	
22	 No	 	 No	 No	 MMF	500mg	bd	
23	 No	 	 No	 No	 No	
24	 No	 	 No	 No	 No	
25	 No	 	 No	 No	 No	
26	 No	 	 Yes	 No	 Aza	75mg	d	MMF	(mycophenolate	mofetil);	Aza	(azathioprine);	NA	(not	available).										 	
